Logo image of TCBP

TC BIOPHARM HOLDINGS PLC-ADR (TCBP) Stock Fundamental Analysis

NASDAQ:TCBP - Nasdaq - US87807D5095 - ADR

0.3661  -0.01 (-3.4%)

Premarket: 0.3755 +0.01 (+2.57%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to TCBP. TCBP was compared to 572 industry peers in the Biotechnology industry. TCBP may be in some trouble as it scores bad on both profitability and health. TCBP has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

TCBP had negative earnings in the past year.
TCBP had a negative operating cash flow in the past year.
TCBP had negative earnings in each of the past 5 years.
TCBP had a negative operating cash flow in each of the past 5 years.
TCBP Yearly Net Income VS EBIT VS OCF VS FCFTCBP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -5M -10M

1.2 Ratios

Looking at the Return On Assets, with a value of -71.77%, TCBP is doing worse than 66.90% of the companies in the same industry.
TCBP has a worse Return On Equity (-293.88%) than 74.51% of its industry peers.
Industry RankSector Rank
ROA -71.77%
ROE -293.88%
ROIC N/A
ROA(3y)-82.72%
ROA(5y)-76.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TCBP Yearly ROA, ROE, ROICTCBP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 1K 2K 3K 4K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TCBP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TCBP Yearly Profit, Operating, Gross MarginsTCBP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -200 -400 -600

More info and screens

1

2. Health

2.1 Basic Checks

TCBP does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TCBP has been increased compared to 1 year ago.
There is no outstanding debt for TCBP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TCBP Yearly Shares OutstandingTCBP Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
TCBP Yearly Total Debt VS Total AssetsTCBP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -8.23, we must say that TCBP is in the distress zone and has some risk of bankruptcy.
TCBP has a Altman-Z score of -8.23. This is in the lower half of the industry: TCBP underperforms 70.62% of its industry peers.
TCBP has a Debt/Equity ratio of 1.07. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.07, TCBP is not doing good in the industry: 79.65% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.07
Debt/FCF N/A
Altman-Z -8.23
ROIC/WACCN/A
WACC5.11%
TCBP Yearly LT Debt VS Equity VS FCFTCBP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 -5M -10M -15M

2.3 Liquidity

A Current Ratio of 1.09 indicates that TCBP should not have too much problems paying its short term obligations.
TCBP has a worse Current ratio (1.09) than 87.26% of its industry peers.
A Quick Ratio of 1.09 indicates that TCBP should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.09, TCBP is not doing good in the industry: 85.31% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.09
Quick Ratio 1.09
TCBP Yearly Current Assets VS Current LiabilitesTCBP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for TCBP have decreased strongly by -1265.80% in the last year.
Looking at the last year, TCBP shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)-1265.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%454.58%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, TCBP will show a very strong growth in Earnings Per Share. The EPS will grow by 41.42% on average per year.
The Revenue is expected to decrease by -41.42% on average over the next years. This is quite bad
EPS Next Y99.78%
EPS Next 2Y41.42%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

TCBP Yearly Revenue VS EstimatesTCBP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M
TCBP Yearly EPS VS EstimatesTCBP Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 -500 -1K -1.5K -2K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TCBP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TCBP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TCBP Price Earnings VS Forward Price EarningsTCBP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TCBP Per share dataTCBP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as TCBP's earnings are expected to grow with 41.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TCBP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TC BIOPHARM HOLDINGS PLC-ADR

NASDAQ:TCBP (1/21/2025, 8:00:02 PM)

Premarket: 0.3755 +0.01 (+2.57%)

0.3661

-0.01 (-3.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)12-13 2022-12-13/bmo
Inst Owners1.77%
Inst Owner Change-74.85%
Ins Owners0%
Ins Owner Change0%
Market Cap3.00M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short Ratio0.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-97.86%
PT rev (3m)-97.86%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.22
P/tB 1.74
EV/EBITDA N/A
EPS(TTM)-4.98
EYN/A
EPS(NY)-0.01
Fwd EYN/A
FCF(TTM)-1.91
FCFYN/A
OCF(TTM)-1.82
OCFYN/A
SpS0
BVpS0.3
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -71.77%
ROE -293.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-82.72%
ROA(5y)-76.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 1.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.09
Quick Ratio 1.09
Altman-Z -8.23
F-Score1
WACC5.11%
ROIC/WACCN/A
Cap/Depr(3y)28.28%
Cap/Depr(5y)69.6%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1265.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%454.58%
EPS Next Y99.78%
EPS Next 2Y41.42%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-19.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.79%
OCF growth 3YN/A
OCF growth 5YN/A